Welcome to our dedicated page for Corcept Therapeutics news (Ticker: CORT), a resource for investors and traders seeking the latest updates and insights on Corcept Therapeutics stock.
Corcept Therapeutics reports developments in cortisol modulation therapies for severe endocrinologic, oncologic, metabolic and neurologic disorders. The company markets Korlym for endogenous Cushing’s syndrome and Lifyorli, a relacorilant regimen approved with nab-paclitaxel for certain adults with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.
Recurring news includes financial results, revenue guidance, clinical data from programs such as ROSELLA, DAZALS and MOMENTUM, FDA-related updates, medical-conference presentations, publications, patent matters and distribution arrangements tied to Korlym, Lifyorli and the company’s selective cortisol modulator pipeline.
Corcept Therapeutics (NASDAQ: CORT) presented late-breaking MOMENTUM trial data at ACC 2026 showing 27.3% prevalence of endogenous hypercortisolism among 1,086 patients with resistant hypertension (297 patients).
The results align with Corcept’s CATALYST trial and show higher prevalence (32.6%–36.6%) in high‑risk subgroups with elevated HbA1c and multi‑drug blood pressure regimens.
Corcept Therapeutics (NASDAQ: CORT) announced FDA approval on March 25, 2026 for Lifyorli (relacorilant) plus nab-paclitaxel to treat adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic regimens, including at least one with bevacizumab.
Approval followed the 381‑patient ROSELLA trial: OS benefit of 4.1 months (16.0 vs 11.9 months; HR 0.65; p=0.0004) and PFS improvement (HR 0.70; p=0.008). Lifyorli is the first FDA‑approved selective glucocorticoid receptor antagonist; safety notes include neutropenia, infections, adrenal insufficiency and embryo‑fetal toxicity.
Corcept Therapeutics (NASDAQ: CORT) reported 2025 revenue of $761.4M and net income of $99.7M. Fourth-quarter revenue was $202.1M with Q4 net income of $24.3M (diluted EPS $0.20). Cash and investments totaled $532.4M at year-end. Management provided 2026 revenue guidance of $900M–$1,000M and highlighted key clinical readouts, a July 11, 2026 PDUFA date for relacorilant in platinum-resistant ovarian cancer, and plans for a Phase 3 ALS trial.
Corcept (NASDAQ: CORT) said the U.S. Court of Appeals for the Federal Circuit found that Teva Pharmaceuticals’ marketing of a generic Korlym does not infringe two Corcept patents covering methods for safely co-administering Korlym with CYP3A4 inhibitors.
The ruling affirms a December 2023 District Court verdict. Corcept said it is disappointed and is considering whether to seek further judicial review.
Corcept Therapeutics (NASDAQ: CORT) will report fourth quarter and full‑year 2025 financial results and provide a corporate update on February 24, 2026. A conference call and listen‑only webcast will be held at 5:00 p.m. ET (2:00 p.m. PT), with registration required for dial‑in access and PINs.
A replay will be posted on the Investors / Events tab of Corcept.com after the call.
Corcept (NASDAQ: CORT) reported that its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer met both dual primary endpoints. The combination reduced the risk of death by 35% (HR 0.65; p=0.0004) and extended median overall survival to 16.0 months vs 11.9 months (difference 4.1 months). ROSELLA also showed a 30% reduction in progression risk (HR 0.70; p=0.008). The regimen was well tolerated with similar adverse event profiles versus nab-paclitaxel alone. The NDA is under FDA review with a PDUFA date of July 11, 2026, and an MAA is under EMA review. ROSELLA enrolled 381 patients randomized 1:1 across multiple regions.
Corcept (NASDAQ: CORT) announced that the FDA issued a Complete Response Letter for the NDA for relacorilant as a treatment for hypertension secondary to hypercortisolism. The FDA acknowledged the pivotal GRACE trial met its primary endpoint and found the GRADIENT trial provided confirmatory evidence, but concluded additional evidence of effectiveness is needed before a favorable benefit‑risk assessment can be made.
Corcept said it is surprised and disappointed, remains committed to patients, and will meet with the FDA as soon as possible to discuss next steps.
Corcept Therapeutics (NASDAQ: CORT) reported Q3 2025 revenue of $207.6M (vs. $182.5M in Q3 2024) and net income of $19.7M. Cash and investments were $524.2M at Sept 30, 2025. The company adjusted 2025 revenue guidance to $800–$850M citing prior specialty pharmacy capacity constraints and added a new specialty pharmacy on Oct 1.
Key development milestones include a Dec 30, 2025 PDUFA for relacorilant in hypercortisolism, a Jul 11, 2026 PDUFA for relacorilant in platinum-resistant ovarian cancer, ROSELLA meeting its primary endpoint, upcoming BELLA/BELLA parts and new Phase 2/1b oncology and Phase 3 ALS trials.
Corcept Therapeutics (NASDAQ: CORT) will report third quarter 2025 financial results and provide a corporate update on November 4, 2025. The company will host a conference call on that date at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Participants must register in advance to receive a dial-in number and a unique access PIN; a listen-only webcast will also be available. A replay will be posted on the Investors / Events tab at Corcept.com.
Corcept (NASDAQ: CORT) presented late-breaking Phase 3 ROSELLA data at ESMO 2025 showing relacorilant plus nab-paclitaxel improved outcomes in platinum-resistant ovarian cancer, including patients with prior PARP inhibitor (PARPi) exposure.
Key results: prior PARPi subgroup PFS HR 0.60 (p=0.0035), progressed-on-PARPi subgroup PFS HR 0.56 (p=0.0046) with median PFS 7.36 months. ROSELLA met primary PFS endpoint HR 0.70 (p=0.0076) and interim OS favored the combination HR 0.69 (p=0.0121). Safety in PARPi subgroups was comparable to nab-paclitaxel alone. Corcept also expanded the Phase 2 BELLA trial to three arms; initial BELLA results expected in late 2026.